TCRT · Alaunos Therapeutics, Inc. · Debt
$1.74
-0.10 (-5.43%)
At close · Nov 6
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.42M
Shares
2.54M
Volume · Nov 6
101.46K
Avg daily vol (3M)
7.43M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent debt carrying amount | 2024-12-31 | USD 0 | 10-K filed 2025-03-31 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1107421
CUSIP
98973P309
13F (30d)
18 filings
11 filers
Visit website
Investor relations